Protective role of salbutamol against aminophylline-induced arrhythmias in an hPSC-based cardiac model

Investor logo

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SCUREK Martin KABANOV Daniil KLIMOVIC Simon BECKEROVA Deborah PEŠL Martin PRIBYL Jan BÉBAROVÁ Markéta ROTREKL Vladimír BRAT Kristian

Year of publication 2025
Type Paper in proceedings
Conference EUROPEAN RESPIRATORY JOURNAL
MU Faculty or unit

Faculty of Medicine

Citation
web https://publications.ersnet.org/content/erj/66/suppl69/pa1410
Doi https://doi.org/10.1183/13993003.congress-2025.PA1410
Keywords Cellular biosensor; atomic force microscopy; arrhythmia; cardiomyocytes; drug screening; drug cardiotoxicity; conduction; pluripotent stem cells; biomechanical properties.
Description Introduction: Aminophylline and salbutamol are commonly used in clinical practice to treat obstructive lung diseases. While the adverse effects of individual bronchodilators, including arrhythmias, are well-documented, the potential side effects of their combined use remain largely unknown. Aims: This study aimed to evaluate the arrhythmogenic potential of aminophylline and salbutamol co-administration in vitro. Methods: We used an established atomic force microscopy (AFM) model integrated with cardiac organoids derived from human pluripotent stem cells (hPSC-CMs). The study focused on assessment of chronotropic, inotropic, and arrhythmogenic effects of salbutamol alone and in combination with aminophylline. To detect arrhythmic events, we employed heart rate/beat rate variability (HRV/BRV) analysis in AFM recordings from hPSC-CMs. Results: Salbutamol reduced aminophylline-induced arrhythmogenicity, likely through endothelial nitric oxide synthase activation via beta-2 adrenergic receptors. These findings were validated using hPSC-CMs derived from two distinct cell lines (CCTL4 and CCTL12). Conclusion: Our results suggest that salbutamol, beyond its bronchodilator properties, may increase the cardiovascular safety of aminophylline by reducing its arrhythmogenic potential.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info